Pozen at outperform by RBC

RBC Capital Markets analyst Ken Trbovich rated Pozen, Inc. at outperform, speculative risk, after the company issued new guidance following antitrust clearance of its agreement with AstraZeneca. Pozen could benefit from additional development and regulatory milestones. In addition, Pozen has a phase-3 sized proof of concept study for PN-200, including 400 patients at 66 centers. The trial is expected to take a year to complete. Shares of the Chapel Hill, N.C.-based development-stage company were down 55 cents, or 4.23%, at $12.46. (Nasdaq: POZN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.